Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 6 | 2021 | 207 | 0.810 |
Why?
|
| Mycoses | 4 | 2012 | 45 | 0.590 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 101 | 0.460 |
Why?
|
| Ascomycota | 1 | 2012 | 12 | 0.410 |
Why?
|
| Bursitis | 1 | 2012 | 15 | 0.400 |
Why?
|
| Knee Injuries | 1 | 2012 | 47 | 0.390 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 314 | 0.360 |
Why?
|
| Tuberculosis | 2 | 2012 | 270 | 0.330 |
Why?
|
| Antitubercular Agents | 2 | 2012 | 76 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 5 | 2000 | 737 | 0.270 |
Why?
|
| Patient Compliance | 1 | 2009 | 349 | 0.270 |
Why?
|
| Imipenem | 2 | 1997 | 3 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2020 | 191 | 0.240 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 29 | 0.230 |
Why?
|
| Pleural Effusion | 2 | 2020 | 35 | 0.210 |
Why?
|
| Ganciclovir | 1 | 2002 | 18 | 0.200 |
Why?
|
| Lithiasis | 1 | 2002 | 1 | 0.200 |
Why?
|
| Actinomycosis | 1 | 2002 | 3 | 0.200 |
Why?
|
| Hemoptysis | 1 | 2002 | 8 | 0.200 |
Why?
|
| Bronchial Diseases | 1 | 2002 | 12 | 0.200 |
Why?
|
| Histoplasmosis | 1 | 2002 | 23 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 66 | 0.190 |
Why?
|
| Bronchi | 1 | 2002 | 82 | 0.190 |
Why?
|
| Antifungal Agents | 3 | 2020 | 120 | 0.190 |
Why?
|
| Lung Diseases | 2 | 2018 | 170 | 0.170 |
Why?
|
| Ampicillin | 2 | 1997 | 12 | 0.170 |
Why?
|
| DNA Polymerase III | 1 | 2000 | 28 | 0.170 |
Why?
|
| Gram-Positive Bacteria | 1 | 2000 | 36 | 0.170 |
Why?
|
| Strongyloides stercoralis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Uracil | 1 | 2000 | 30 | 0.170 |
Why?
|
| Strongyloidiasis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2020 | 12 | 0.170 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 75 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2002 | 313 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 347 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2000 | 451 | 0.140 |
Why?
|
| Mycobacterium haemophilum | 1 | 2017 | 5 | 0.140 |
Why?
|
| Critical Care | 2 | 2020 | 399 | 0.140 |
Why?
|
| Mycobacterium Infections | 1 | 2017 | 16 | 0.140 |
Why?
|
| Thienamycins | 1 | 1997 | 1 | 0.140 |
Why?
|
| Tobramycin | 1 | 1997 | 6 | 0.140 |
Why?
|
| Lung | 1 | 2002 | 920 | 0.140 |
Why?
|
| Penicillins | 1 | 1997 | 29 | 0.140 |
Why?
|
| Gentamicins | 1 | 1997 | 23 | 0.140 |
Why?
|
| Phylogeny | 2 | 2021 | 337 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1997 | 100 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2017 | 106 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 2 | 1993 | 31 | 0.130 |
Why?
|
| Humans | 24 | 2021 | 59458 | 0.130 |
Why?
|
| Middle Aged | 10 | 2021 | 16336 | 0.120 |
Why?
|
| Staphylococcus | 2 | 1999 | 17 | 0.120 |
Why?
|
| DNA, Bacterial | 2 | 2012 | 260 | 0.110 |
Why?
|
| Rickettsiaceae | 1 | 1993 | 1 | 0.110 |
Why?
|
| Rickettsiaceae Infections | 1 | 1993 | 5 | 0.110 |
Why?
|
| Cryptococcosis | 2 | 2008 | 76 | 0.100 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 1953 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2004 | 108 | 0.100 |
Why?
|
| Male | 12 | 2021 | 27790 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2012 | 143 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 13 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 27 | 0.090 |
Why?
|
| HIV-1 | 2 | 2010 | 692 | 0.090 |
Why?
|
| Bronchoscopy | 2 | 2020 | 86 | 0.090 |
Why?
|
| Skin Diseases, Infectious | 1 | 1990 | 10 | 0.090 |
Why?
|
| Peritonitis | 1 | 1990 | 35 | 0.090 |
Why?
|
| Massachusetts | 2 | 2009 | 2022 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2012 | 458 | 0.090 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 365 | 0.090 |
Why?
|
| Colitis | 1 | 1990 | 74 | 0.080 |
Why?
|
| Rifampin | 1 | 2009 | 23 | 0.080 |
Why?
|
| Isoniazid | 1 | 2009 | 11 | 0.080 |
Why?
|
| Enterococcus faecium | 2 | 2020 | 6 | 0.080 |
Why?
|
| HIV Infections | 2 | 2010 | 914 | 0.080 |
Why?
|
| Amphotericin B | 1 | 2008 | 21 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 227 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 49 | 0.080 |
Why?
|
| Oxazoles | 1 | 1988 | 10 | 0.080 |
Why?
|
| Streptococcus | 1 | 1988 | 17 | 0.080 |
Why?
|
| Triazoles | 1 | 2008 | 51 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2008 | 53 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 934 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 206 | 0.060 |
Why?
|
| Candida | 2 | 2020 | 35 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2009 | 5287 | 0.060 |
Why?
|
| Time Factors | 3 | 2002 | 3621 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2018 | 1204 | 0.060 |
Why?
|
| Liver | 1 | 2009 | 796 | 0.060 |
Why?
|
| Student Health Services | 1 | 2004 | 6 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2004 | 37 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 2057 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 134 | 0.050 |
Why?
|
| Adult | 6 | 2009 | 15698 | 0.050 |
Why?
|
| Aged | 4 | 2020 | 13424 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 155 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6079 | 0.050 |
Why?
|
| Incidence | 3 | 2012 | 1239 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2002 | 98 | 0.050 |
Why?
|
| Female | 6 | 2017 | 30772 | 0.050 |
Why?
|
| Superinfection | 1 | 2002 | 10 | 0.050 |
Why?
|
| Granuloma | 1 | 2002 | 41 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 90 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 149 | 0.050 |
Why?
|
| Calcinosis | 1 | 2002 | 79 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2002 | 355 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2002 | 215 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 496 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2021 | 62 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2021 | 66 | 0.040 |
Why?
|
| Enterococcus | 1 | 2000 | 10 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Thiabendazole | 1 | 2020 | 3 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2020 | 6 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2020 | 13 | 0.040 |
Why?
|
| Daptomycin | 1 | 2020 | 9 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 32 | 0.040 |
Why?
|
| Ivermectin | 1 | 2020 | 11 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 801 | 0.040 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2000 | 12 | 0.040 |
Why?
|
| Abdomen | 1 | 2020 | 91 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 103 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 5126 | 0.040 |
Why?
|
| Young Adult | 1 | 2009 | 4274 | 0.040 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 1999 | 11 | 0.040 |
Why?
|
| Methicillin Resistance | 1 | 1999 | 22 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2000 | 170 | 0.040 |
Why?
|
| Candidiasis | 2 | 2008 | 45 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 153 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1997 | 805 | 0.040 |
Why?
|
| Pulmonary Atelectasis | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2018 | 28 | 0.040 |
Why?
|
| Streptomycin | 1 | 1997 | 12 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 228 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 33 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 30 | 0.040 |
Why?
|
| Agar | 1 | 1997 | 3 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1999 | 275 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 180 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1997 | 70 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 1997 | 110 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1997 | 115 | 0.030 |
Why?
|
| Culture Media | 1 | 1997 | 77 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 430 | 0.030 |
Why?
|
| Zinc | 1 | 1997 | 91 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1997 | 473 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1597 | 0.030 |
Why?
|
| Temperature | 1 | 1997 | 296 | 0.030 |
Why?
|
| Viral Load | 2 | 2010 | 220 | 0.030 |
Why?
|
| Base Sequence | 2 | 2000 | 1302 | 0.030 |
Why?
|
| Pneumonia | 1 | 2018 | 282 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 1513 | 0.030 |
Why?
|
| Drug Stability | 1 | 1994 | 141 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 226 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 2 | 1997 | 47 | 0.030 |
Why?
|
| Base Composition | 1 | 1993 | 27 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3072 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1993 | 78 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 1993 | 68 | 0.030 |
Why?
|
| Lactobacillus acidophilus | 1 | 1992 | 1 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1997 | 1286 | 0.020 |
Why?
|
| Living Donors | 1 | 2012 | 72 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1993 | 191 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 446 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 3 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 8 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 9 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 18 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 115 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 1990 | 172 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 140 | 0.020 |
Why?
|
| Phenotype | 1 | 1993 | 1138 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 411 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 332 | 0.020 |
Why?
|
| Norfloxacin | 1 | 1988 | 2 | 0.020 |
Why?
|
| Oxazolidinones | 1 | 1988 | 13 | 0.020 |
Why?
|
| Aspergillosis | 1 | 2008 | 40 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 1988 | 21 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 440 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1988 | 54 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 4990 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1988 | 41 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 142 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 763 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 147 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 715 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1128 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1119 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 648 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2004 | 10 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 2377 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 774 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2004 | 158 | 0.010 |
Why?
|
| Universities | 1 | 2004 | 144 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2004 | 279 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 19678 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 1255 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 28 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2000 | 90 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 289 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 326 | 0.010 |
Why?
|
| Vancomycin | 1 | 1999 | 36 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 648 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 191 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2000 | 259 | 0.010 |
Why?
|
| Virus Replication | 1 | 2000 | 305 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 1926 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 1992 | 9 | 0.010 |
Why?
|
| Lactams | 1 | 1992 | 18 | 0.010 |
Why?
|
| United States | 1 | 2004 | 7432 | 0.010 |
Why?
|